시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 발작성야간혈색뇨증(PNH) 시장 보고서(2025년)
Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025
상품코드 : 1825491
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,686,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,665,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,644,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

발작성야간혈색뇨증(PNH) 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 9.5%로 67억 1,000만 달러로 성장합니다. 예측 기간의 성장은 인구 고령화, 자가 투여 치료에 대한 수요 증가, 의료 서비스 접근성 증가, 동반 질환 유병률 증가, 맞춤형 의료에 대한 수요 증가에 기인하는 것으로 보입니다. 예측 기간의 주요 동향으로는 디지털 헬스 기술, 새로운 혁신적 치료법 개발, 유전자 치료의 채택, 조기 개입 등이 있습니다.

향후 5년간 9.5%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 영국과 스위스에서 조달되는 보체 억제제 생물제제의 비용을 상승시키고, 생명을 구하는 수혈을 지연시키고, 혈액내과 지출을 증가시킴으로써 미국을 괴롭힐 것으로 예측됩니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

혈액 및 골수 관련 질환의 유병률 증가는 발작성야간혈색소뇨증(PNH) 시장의 성장을 가속할 것으로 예측됩니다. 혈액질환은 혈액 및 그 성분의 생산, 기능, 구성에 영향을 미치는 질환이며, 골수 관련 질환은 적혈구, 백혈구, 혈소판의 생산이 불충분하거나 손상 또는 결함이 있는 혈액세포가 생성되는 질환입니다. 골수 부전과 관련된 희귀 혈액질환인 PNH는 유전자 변이로 인해 적혈구와 혈소판의 기능이 파괴되어 발생합니다. 예를 들어 2022년 8월 호주암협회(Cancer Australia)는 2022년에 약 5,202건의 백혈병이 새로 발생할 것으로 예상되며, 그 중 남성이 3,198건, 여성이 2,004건이라고 보고했습니다. 85세까지 백혈병 진단을 받을 가능성은 전체 58명 중 1명(1.7%)이며, 여성(77명 중 1명, 1.3%)에 비해 남성(47명 중 1명, 2.1%)의 위험이 더 높습니다. 이러한 혈액 및 골수 질환의 유병률 증가가 PNH 시장의 성장을 촉진하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

Paroxysmal nocturnal hemoglobinuria (PNH) is an uncommon hematological disorder that is acquired, and it is characterized by the abnormal breakdown of red blood cells (hemolysis) due to a deficiency of certain proteins found on the surface of blood cells. This condition is debilitating and can lead to premature death, as well as impaired blood cell production. PNH manifests through a variety of symptoms, including fatigue, shortness of breath, abdominal pain, and the formation of blood clots known as thrombosis.

The primary approaches to treating paroxysmal nocturnal hemoglobinuria (PNH) involve the use of medications, bone marrow transplantation, blood transfusion, immunosuppressive therapy, and other methods. Medications are substances specially designed and formulated for the diagnosis, treatment, prevention, or alleviation of medical conditions, diseases, or symptoms in both humans and animals. Various diagnostic techniques, such as flow cytometry and high-resolution mass spectrometry, are utilized by a range of end users, including hospitals, clinics, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The paroxysmal nocturnal hemoglobinuria market research report is one of a series of new reports from The Business Research Company that provides paroxysmal nocturnal hemoglobinuria market statistics, including paroxysmal nocturnal hemoglobinuria industry global market size, regional shares, competitors with a paroxysmal nocturnal hemoglobinuria market share, detailed paroxysmal nocturnal hemoglobinuria market segments, market trends and opportunities and any further data you may need to thrive in the paroxysmal nocturnal hemoglobinuria industry. This paroxysmal nocturnal hemoglobinuria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The paroxysmal nocturnal hemoglobinuria (pnh) market size has grown rapidly in recent years. It will grow from $4.24 billion in 2024 to $4.67 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to growing demand for paroxysmal nocturnal hemoglobinuria treatment, rising disposable incomes, government initiatives, rising healthcare expenditure.

The paroxysmal nocturnal hemoglobinuria (pnh) market size is expected to see strong growth in the next few years. It will grow to $6.71 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to aging population, growing demand for self-administered treatments, increasing access to healthcare, increasing prevalence of comorbidities, growing demand for personalized medicine. Major trends in the forecast period include digital health technologies, development of new and innovative treatments,adoption of gene therapy, early intervention.

The forecast of 9.5% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of complement inhibitor biologics sourced from the UK and Switzerland, thereby delaying life-saving infusions and elevating hematology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of blood disorders and bone marrow-related conditions is expected to drive the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood disorders are conditions that affect the production, function, and composition of blood and its components, while bone marrow-related disorders involve insufficient production of red, white blood cells, or platelets, or the production of damaged or defective blood cells. PNH, a rare blood disorder linked to bone marrow failure, occurs when a genetic mutation disrupts the function of red blood cells and platelets. For example, in August 2022, Cancer Australia reported that around 5,202 new cases of leukemia were expected in 2022, with 3,198 cases in males and 2,004 cases in females. The likelihood of being diagnosed with leukemia by age 85 is 1 in 58 (1.7%) overall, with males at a higher risk (1 in 47 or 2.1%) compared to females (1 in 77 or 1.3%). This increasing incidence of blood and bone marrow disorders is driving the growth of the PNH market.

The growing requirement for blood transfusions is poised to be a driving force behind the expansion of the paroxysmal nocturnal hemoglobinuria (PNH) market. Blood transfusion is a medical procedure that involves the transfer of blood or blood products from a donor to a recipient. For individuals with paroxysmal nocturnal hemoglobinuria (PNH), blood transfusions can offer temporary relief from the symptoms and complications associated with this condition. For instance, in June 2023, the World Health Organization, an intergovernmental organization headquartered in Switzerland, reported that high-income nations, which account for only 16% of the global population, contributed significantly to blood donations, comprising 40% of the total 118.5 million blood donations made worldwide. Additionally, in December 2022, the Government of Canada reported that the United Kingdom experienced an upsurge in blood donations, with 1.7 million donations made across the country in 2021. Consequently, the escalating demand for blood transfusions is a key factor driving the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.

Leading companies in the paroxysmal nocturnal hemoglobinuria (PNH) market are focusing on the development of innovative therapies, such as injectable C5 inhibitors, to maintain their competitive edge. Injectable C5 inhibitors are monoclonal antibodies that block complement component C5, helping to reduce inflammation and tissue damage associated with autoimmune diseases, including PNH. For example, in February 2024, Chugai Pharmaceutical Co., a Japan-based pharmaceutical company, received priority review approval from China's National Medical Products Administration (NMPA) for its PNH treatment. This makes China the first country to approve PIASKY, allowing it to enter negotiations for the National Reimbursement Drug List (NRDL) within the same year. PNH, a rare disease, affects an estimated 12,740 individuals in China, presenting substantial market opportunities.

In March 2024, Gilead Sciences, Inc., a US-based biopharmaceutical company specializing in developing medicines for life-threatening diseases, acquired Cymabay Therapeutics, Inc. for $4.3 billion. This acquisition strengthens Gilead's liver disease portfolio, particularly with the addition of seladelpar, a promising treatment for primary biliary cholangitis that addresses significant unmet medical needs. Cymabay Therapeutics, Inc., also based in the US, is focused on developing seladelpar as a potential treatment for paroxysmal nocturnal hemoglobinuria (PNH).

Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.

North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the paroxysmal nocturnal hemoglobinuria (PNH) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The paroxysmal nocturnal hemoglobinuria (PNH) market consists of revenues earned by entities by providing services such as gene therapy, stem cell transplant and complete blood count test (CBC). The market value includes the value of related goods sold by the service provider or included within the service offering. The paroxysmal nocturnal hemoglobinuria (PNH) market also includes sales of Eculizumab and Ravulizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on paroxysmal nocturnal hemoglobinuria (pnh) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for paroxysmal nocturnal hemoglobinuria (pnh) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The paroxysmal nocturnal hemoglobinuria (pnh) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Characteristics

3. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Trends And Strategies

4. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Growth Analysis And Strategic Analysis Framework

6. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Segmentation

7. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Regional And Country Analysis

8. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

9. China Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

10. India Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

11. Japan Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

12. Australia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

13. Indonesia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

14. South Korea Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

15. Western Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

16. UK Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

17. Germany Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

18. France Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

19. Italy Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

20. Spain Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

21. Eastern Europe Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

22. Russia Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

23. North America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

24. USA Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

25. Canada Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

26. South America Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

27. Brazil Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

28. Middle East Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

29. Africa Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

30. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Landscape And Company Profiles

31. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Other Major And Innovative Companies

32. Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

34. Recent Developments In The Paroxysmal Nocturnal Hemoglobinuria (PNH) Market

35. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기